Biotechnology
Commented by Stefan Feulner on September 8th, 2025 | 07:10 CEST
Opendoor, Almonty Industries, BioNTech – Great opportunities outside the tech bubble
While the Nasdaq 100 continued to lose momentum last week, along with leading tech stocks, the crisis metal gold celebrated a new all-time high at USD 3,586 per ounce. The escalating geopolitical crises and the intensifying trade war between the US and China are likely to drive prices for critical raw materials in the long term. Western producers remain attractively valued.
Read
Commented by Nico Popp on September 4th, 2025 | 07:25 CEST
AI reaches medicine – Here is where it has the greatest impact: NetraMark, Siemens Healthineers, Intuitive Surgical
AI is revolutionizing more and more industries. A recent article in Handelsblatt highlights the enormous potential in medicine and names Siemens Healthineers and Intuitive Surgical as the beneficiaries. AI would significantly increase the often-lacking efficiency in industry. According to Handelsblatt, citing analysts from Fortune Business Insights, the market for AI in healthcare could grow by 44% annually to USD 504 billion by 2032. We show where the greatest leverage exists and which companies are still small enough to benefit disproportionately from developments in the coming years.
Read
Commented by Nico Popp on September 4th, 2025 | 07:05 CEST
What comes after the weight loss injection? How does BioNxt intend to outperform Eli Lilly and Novo Nordisk?
The weight loss injection is all the rage. Not only are celebrities shedding significant pounds with it, but many people in our own circles are also losing weight effortlessly thanks to modern GLP-1 receptor agonists. Many patients report that they simply do not feel hungry anymore. This is already having an impact on the restaurant industry in the US – people are ordering more salads and splitting desserts. With Wegovy and similar drugs, one to two teaspoons of tiramisu is enough. But this billion-dollar market is far from reaching all patients. What groundbreaking developments in modern weight loss drugs are already in the pipeline, and how can investors benefit?
Read
Commented by Fabian Lorenz on September 2nd, 2025 | 07:50 CEST
INSIDER ALERT at Evotec! Valneva with new TARGET PRICE! Vidac Pharma stock soon to reach new ALL-TIME HIGH?
Finally! Insiders are sending an important signal at Evotec. The stock has not yet reacted, but in the medium term, this could turn out to be a buy signal. Skepticism still prevails at present. Analysts are bullish on Vidac Pharma. In the fall of 2024, the biotech stock had multiplied in value. Is it now heading back toward its all-time high? According to analysts, significantly higher price gains are possible. Valneva, on the other hand, is not for the faint of heart. After doubling in price within a few weeks, the stock has plummeted again. Analysts recommend buying, but are significantly lowering their price target.
Read
Commented by Armin Schulz on September 2nd, 2025 | 07:25 CEST
After the price corrections: Is now the time for Novo Nordisk, Almonty Industries, and Puma?
Volatile periods offer the greatest opportunities for savvy investors. While the masses are unsettled by price fluctuations, strategic investors have the chance to acquire fundamentally sound stocks at attractive prices. This discipline of keeping calm in the face of uncertainty separates the long-term winners from the losers. Three companies currently deserving of precisely this attention are Novo Nordisk, Almonty Industries, and Puma.
Read
Commented by Stefan Feulner on September 2nd, 2025 | 07:10 CEST
Bayer, BioNxt Solutions, FamiCord AG – Undiscovered gems with strong growth potential
While artificial intelligence has been dominating the headlines for months and tech stocks are reaching record valuations, the biotech sector is leading a shadowy existence on the stock markets. Investors are shying away from the often complex and risky business models, with many stocks trading well below their all-time highs. However, while the spotlight is on AI, significant developments are taking place in the background: clinical trials are reaching key milestones, new therapeutic approaches, such as cell and gene therapies, are advancing, and partnerships with big pharma have increased substantially in recent years.
Read
Commented by Armin Schulz on August 28th, 2025 | 07:15 CEST
The BioNxt Solutions formula: How a simple idea can turn into a billion-dollar business – Without high risk
In the pharmaceutical industry, promising active ingredients often fail due to a simple problem, such as administration. Canadian biotech company BioNxt Solutions has taken on precisely this challenge. With a smart platform for oral dissolvable films and patches, the Vancouver-based innovator could not only make life easier for patients but also open up a lucrative growth opportunity for investors. We took a closer look at the promising technology behind it.
Read
Commented by Fabian Lorenz on August 27th, 2025 | 07:20 CEST
Quick 30% return possible? Novo Nordisk, D-Wave, and NetraMark shares!
Three completely different companies, but all with return potential: AI specialist NetraMark is on the verge of a technical breakout. NetraAI has outperformed ChatGPT and DeepSeek and is gaining more customers. If the breakout occurs, the stock could quickly move toward the analyst price target, representing a potential gain of around 30%. At Novo Nordisk, last week's price gains have almost been lost again. Wegovy's strong market entry in South Korea caused only brief jubilation. Now, competition from Eli Lilly is dampening the mood. At D-Wave, the stock could soon be heading toward new highs again. The Company plans to accelerate its growth in Asia, and new momentum for the stock is expected in September.
Read
Commented by André Will-Laudien on August 26th, 2025 | 07:20 CEST
Big moves! Buying frenzy at Novo Nordisk and PanGenomic Health, Valneva left behind
Things are moving again in the biotech sector! While Novo Nordisk appears to have finally found its footing after three profit warnings, PanGenomic Health continues its upward trend. Since launching its new business model in May, the stock has staged a phenomenal rally of over 1,000%. Meanwhile, Valneva faces a major setback as the US Food and Drug Administration (FDA) has halted approval of the chikungunya vaccine Ixchiq due to severe side effects. This comes as a shock to investors, who are now waiting for the Company to provide further explanations. The stock market has reacted with a sharp drop in the share price. How can investors benefit from the current situation?
Read
Commented by Armin Schulz on August 26th, 2025 | 07:10 CEST
The blueprint for AI-driven drug discovery: How Evotec, NetraMark Holdings, and BioNTech are leveraging new opportunities
The pharmaceutical industry is undergoing a revolution. Artificial intelligence is reducing drug discovery times from years to months and dramatically increasing hit rates. Data-driven predictions and virtual simulations are increasingly replacing costly trial-and-error approaches. This technological leap is already generating concrete successes and massive competitive advantages for pioneers who implemented their digitalization strategies early on. Most recently, an AI-designed drug advanced to clinical trials in record time. Three companies driving this change and reaping its benefits are Evotec, NetraMark Holdings, and BioNTech.
Read